Literature DB >> 20952591

Activation of OX40 augments Th17 cytokine expression and antigen-specific uveitis.

Zili Zhang1, Wenwei Zhong, David Hinrichs, Xiumei Wu, Andrew Weinberg, Mark Hall, Doran Spencer, Keith Wegmann, James T Rosenbaum.   

Abstract

Uveitis is a major and common cause of visual disability. Recent studies have shown that Th17 cells are implicated in the pathogenesis of this serious intraocular disorder. Activated T cells express an inducible costimulatory molecule called OX40, and OX40 in turn promotes the activation and proliferation of these lymphocytes. Nevertheless, it is unclear whether OX40 plays a vital role in enhancing the effector function of Th17 cells as well as the severity of uveitis. In this study, we demonstrated an increase of OX40 transcription in ovalbumin-induced uveitis, whereas anti-OX40L antibody substantially inhibited the antigen-specific ocular inflammation. Next, results from flow cytometry showed that activated Th17 cells expressed OX40, and OX40-activating antibody significantly augmented the production of Th17 cytokines in vitro. To validate the impact of OX40 in vivo, we stimulated ovalbumin-specific T cells with the OX40-activating antibody. Compared to donor cells without OX40 activation, adoptive transfer of OX40-stimulated lymphocytes elicited more severe ocular inflammation. Furthermore, an interleukin-17-neutralizing antibody attenuated OX40-mediated uveitis. In conclusion, our findings suggest that activation of OX40 augments Th17 cell function and thereby contributes to ocular inflammation. This study thus enhances our knowledge of costimulatory molecule-mediated immunopathological mechanisms of uveitis and suggests a future therapeutic strategy to treat uveitis by the targeting of OX40.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20952591      PMCID: PMC2993299          DOI: 10.2353/ajpath.2010.100353

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  54 in total

Review 1.  CD28-mediated co-stimulation: a quantitative support for TCR signalling.

Authors:  Oreste Acuto; Frédérique Michel
Journal:  Nat Rev Immunol       Date:  2003-12       Impact factor: 53.106

Review 2.  The natural history of uveitis.

Authors:  R B Nussenblatt
Journal:  Int Ophthalmol       Date:  1990-10       Impact factor: 2.031

3.  Expression and function of OX40 ligand on human dendritic cells.

Authors:  Y Ohshima; Y Tanaka; H Tozawa; Y Takahashi; C Maliszewski; G Delespesse
Journal:  J Immunol       Date:  1997-10-15       Impact factor: 5.422

4.  A new model of autoimmune disease. Experimental autoimmune uveoretinitis induced in mice with two different retinal antigens.

Authors:  R R Caspi; F G Roberge; C C Chan; B Wiggert; G J Chader; L A Rozenszajn; Z Lando; R B Nussenblatt
Journal:  J Immunol       Date:  1988-03-01       Impact factor: 5.422

5.  4-1BB and Ox40 are members of a tumor necrosis factor (TNF)-nerve growth factor receptor subfamily that bind TNF receptor-associated factors and activate nuclear factor kappaB.

Authors:  R H Arch; C B Thompson
Journal:  Mol Cell Biol       Date:  1998-01       Impact factor: 4.272

6.  Uveitis and systemic disease.

Authors:  A Rothova; H J Buitenhuis; C Meenken; C J Brinkman; A Linssen; C Alberts; L Luyendijk; A Kijlstra
Journal:  Br J Ophthalmol       Date:  1992-03       Impact factor: 4.638

7.  TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1.

Authors:  Ahjoku Amadi-Obi; Cheng-Rong Yu; Xuebin Liu; Rashid M Mahdi; Grace Levy Clarke; Robert B Nussenblatt; Igal Gery; Yun Sang Lee; Charles E Egwuagu
Journal:  Nat Med       Date:  2007-05-13       Impact factor: 53.440

8.  Selective depletion of myelin-reactive T cells with the anti-OX-40 antibody ameliorates autoimmune encephalomyelitis.

Authors:  A D Weinberg; D N Bourdette; T J Sullivan; M Lemon; J J Wallin; R Maziarz; M Davey; F Palida; W Godfrey; E Engleman; R J Fulton; H Offner; A A Vandenbark
Journal:  Nat Med       Date:  1996-02       Impact factor: 53.440

9.  IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells.

Authors:  Thomas Korn; Estelle Bettelli; Wenda Gao; Amit Awasthi; Anneli Jäger; Terry B Strom; Mohamed Oukka; Vijay K Kuchroo
Journal:  Nature       Date:  2007-06-20       Impact factor: 49.962

10.  Inhibition of autoimmune uveitis by anti-CD4 antibody.

Authors:  L Atalla; M Linker-Israeli; L Steinman; N A Rao
Journal:  Invest Ophthalmol Vis Sci       Date:  1990-07       Impact factor: 4.799

View more
  19 in total

Review 1.  TNF superfamily in inflammatory disease: translating basic insights.

Authors:  Michael Croft; Wei Duan; Heonsik Choi; So-Young Eun; Shravan Madireddi; Amit Mehta
Journal:  Trends Immunol       Date:  2011-12-13       Impact factor: 16.687

2.  Activation of OX40 prolongs and exacerbates autoimmune experimental uveitis.

Authors:  Xiumei Wu; James T Rosenbaum; Grazyna Adamus; Gary L Zhang; Jie Duan; Andrew Weinberg; Zili Zhang
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-10-31       Impact factor: 4.799

3.  The Ox40/Ox40 Ligand Pathway Promotes Pathogenic Th Cell Responses, Plasmablast Accumulation, and Lupus Nephritis in NZB/W F1 Mice.

Authors:  Jonathan Sitrin; Eric Suto; Arthur Wuster; Jeffrey Eastham-Anderson; Jeong M Kim; Cary D Austin; Wyne P Lee; Timothy W Behrens
Journal:  J Immunol       Date:  2017-07-10       Impact factor: 5.422

4.  ADP-ribosylating adjuvant reveals plasticity in cDC1 cells that drive mucosal Th17 cell development and protection against influenza virus infection.

Authors:  Mohammad Arabpour; Cristina Lebrero-Fernandez; Karin Schön; Anneli Strömberg; Vanja Börjesson; Katharina Lahl; Marlies Ballegeer; Xavier Saelens; Davide Angeletti; William Agace; Nils Lycke
Journal:  Mucosal Immunol       Date:  2022-04-13       Impact factor: 8.701

5.  Naturally occurring immunoglobulin M (nIgM) autoantibodies prevent autoimmune diabetes and mitigate inflammation after transplantation.

Authors:  Preeti Chhabra; Kailo Schlegel; Mark D Okusa; Peter I Lobo; Kenneth L Brayman
Journal:  Ann Surg       Date:  2012-10       Impact factor: 12.969

6.  The Costimulatory Receptor OX40 Inhibits Interleukin-17 Expression through Activation of Repressive Chromatin Remodeling Pathways.

Authors:  Xiang Xiao; Xiaomin Shi; Yihui Fan; Chenglin Wu; Xiaolong Zhang; Laurie Minze; Wentao Liu; Rafik M Ghobrial; Peixiang Lan; Xian Chang Li
Journal:  Immunity       Date:  2016-06-14       Impact factor: 31.745

7.  OX40 and OX40L protein expression of tumor infiltrating lymphocytes in non-small cell lung cancer and its role in clinical outcome and relationships with other immune biomarkers.

Authors:  Yayi He; Xiaoshen Zhang; Keyi Jia; Rafal Dziadziuszko; Sha Zhao; Juan Deng; Hao Wang; Fred R Hirsch; Caicun Zhou
Journal:  Transl Lung Cancer Res       Date:  2019-08

Review 8.  OX40, OX40L and Autoimmunity: a Comprehensive Review.

Authors:  Gwilym J Webb; Gideon M Hirschfield; Peter J L Lane
Journal:  Clin Rev Allergy Immunol       Date:  2016-06       Impact factor: 8.667

9.  Explant Modeling of the Immune Environment of Head and Neck Cancer.

Authors:  Shay Sharon; Thomas Duhen; Shelly Bambina; Jason Baird; Rom Leidner; Bryan Bell; Nardy Casap; Marka Crittenden; Swetha Vasudevan; Maria Jubran; Nataly Kravchenko-Balasha; Michael Gough
Journal:  Front Oncol       Date:  2021-06-17       Impact factor: 6.244

10.  OX40 ligand expression abrogates the immunosuppressive function of retinal pigment epithelium.

Authors:  Matthew A Cunningham; Zhuqing Li; Baoying Liu; Steven Yeh; Robert B Nussenblatt
Journal:  J Ophthalmic Inflamm Infect       Date:  2013-01-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.